Head-to-head evidence
HM15275 vs UBT251
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
HM15275
Developed by Hanmi Pharmaceutical
NCT06481098 · Phase 1 · completed
The trial randomized participants against a matched placebo with full blinding, but its primary measures were safety and tolerability rather than a body-weight or metabolic efficacy outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: January 2027 · NCT07205900 (registry estimate)
UBT251
Developed by Novo Nordisk under a licence from United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07395687 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HM15275's landscape · UBT251's landscape